Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 5/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.52 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.52 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992218 | 1.00 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4990088 | 0.84 | MEN1 (0.59) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4990101 | 0.84 | MEN1 (0.59) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL5001677 | 0.84 | PTPN7 (0.54) | ALDH1A1HTTPTPN7PTPN12PTPN22 | |
| SCHEMBL5001676 | 0.84 | PTPN7 (0.54) | ALDH1A1HTTPTPN7PTPN12PTPN22 | |
| SCHEMBL5191050 | 0.83 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4996875 | 0.82 | RECQL (0.67) | SMN1; SMN2RECQLHIF1AEGFRPDGFRB | |
| SCHEMBL4996892 | 0.82 | RECQL (0.67) | SMN1; SMN2RECQLHIF1AEGFRPDGFRB | |
| SCHEMBL5191708 | 0.82 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL12507433 | 0.82 | RECQL (0.67) | SMN1; SMN2RECQLHIF1AEGFRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371773-B2 | Breast cancer resistance protein (BCRP) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-13 | — | — | US | claimed |
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-06-15 | — | — | US | claimed |
| EP-1591117-A1 | BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2005-11-02 | — | — | EP | claimed |
| US-7371773-B2 | Breast cancer resistance protein (BCRP) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591117-A1 | BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | ABCC1, OSBP, OSBPL3 | PDE4A 4607/4885PDE4B 4797/4885PDE4C 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.